Edina Cenko/Redcliffe Cardiology and Erik Stroes/amsterdamumc.nl
Sep 13, 2026, 16:51
Edina Cenko: AZURE-HeFH Highlights the LDL-C Treatment Gap in HeFH
Edina Cenko, Past-Chairperson ESC Working Group on Coronary Pathophysiology and Microcirculation at European Society of Cardiology, shared on LinkedIn:
“Presented by Erik Stroes at ESC Congress 2026, baseline cohort data from the Phase 3 AZURE-HeFH trial evaluating the novel oral PCSK9 inhibitor laroprovstat vs placebo.
Lifelong cumulative exposure makes aggressive LDL-C lowering essential in HeFH—yet less than 25% hit guideline targets on conventional oral LLT.
- N is 472 genetically or clinically confirmed HeFH participants
- Approximately 21% with prior ASCVD
- 94% on statins (more than 80% high-intensity) and 73.1% on ezetimibe
- Mean baseline LDL-C: 2.95 mmol/L despite intensive combination background therapy
These findings underline the profound implementation gap in HeFH.
Looking forward to primary 12-week and 52-week safety or efficacy outcomes.”
Other posts featuring Edina Cenko on Hemostasis Today.
-
Oct 27, 2026, 23:04Stefano Navarro: Hypertension Reprogrammes Megakaryocytes and Increases Platelet Responsiveness to Thrombin
-
Oct 27, 2026, 23:03Enrique M. San Norberto García: What Is the Best Treatment for Femoropopliteal in-Stent Restenosis
-
Oct 27, 2026, 23:01Mandy-Lyn Crispim: One Donation Can Help Save More Than One Life
-
Oct 27, 2026, 23:00Teresa Buzzoni: AABB 2026 Through the Eyes of a Newcomer to the Blood Industry
-
Oct 27, 2026, 22:59Josephine Cantu: The Incredible Science Behind Blood Clotting – A Life-Saving Process
-
Oct 27, 2026, 22:56Edward Lee Carter: First Factor XIa Inhibitor Approved Worldwide – U.S. FDA Decision Expected in November
-
Oct 27, 2026, 22:56Anne Troldborg: Preventing Thrombosis in SLE Before the First Event
-
Oct 27, 2026, 22:53Shadi Tabibian: Tazehnameh November 2026 Covers Key Developments in Hemophilia Care
-
Oct 27, 2026, 22:52Danny Hsu: THANZ Makes History With Its First Dedicated HHT Symposium at Blood 2026